Ab­b­Vie-Al­ler­gan com­plete, but crit­ics con­tin­ue to raise an­ti-com­pet­i­tive con­cerns

5 years ago
Deals
Pharma

As Bio­Marin’s lead ri­val wanes, Pfiz­er and Sang­amo post a promis­ing up­date for he­mo­phil­ia A gene ther­a­py

5 years ago
R&D
Cell/Gene Tx

Ab­b­Vie beefs up the im­munol­o­gy pipeline, bet­ting up to $865M on a PhII-ready drug — and fu­el­ing a biotech stock ...

5 years ago
Deals

Tecen­triq pass­es neoad­ju­vant breast can­cer tri­al as Roche looks for ear­ly start on the next big check­point ...

5 years ago
R&D

FDA of­fers sta­tis­ti­cal guid­ance for tri­als im­pact­ed by Covid-19

5 years ago
FDA+
Coronavirus

Covid-19 roundup: Roche's Actem­ra marred by neg­a­tive re­sults; Here comes an­oth­er sin­gle-armed remde­sivir tri­al

5 years ago
Coronavirus

Chi­nese vac­cine de­vel­op­ers have be­gun to shed some se­cre­cy around Covid-19 can­di­dates. What do we know?

5 years ago
China
Coronavirus

Two Bay Area up­starts out to de­liv­er on cell ther­a­py 2.0 join forces on a quest: pur­su­ing a Holy Grail in on­col­o­gy ...

5 years ago
Deals
Cell/Gene Tx

UK in­ves­ti­ga­tors say a drug re­duced Covid-19 deaths for the first time. The world pon­ders what to do next

6 years ago
FDA+
Coronavirus

Avid­i­ty tops up IPO at $298M; Bris­tol My­ers keeps a Cel­gene dis­cov­ery pact alive

6 years ago
News Briefing

Bio­Marin spells out a trou­bling slide in Fac­tor VI­II lev­els for its big block­buster con­tender val­rox

6 years ago
R&D
Cell/Gene Tx

Mer­ck eats the lunch Bris­tol My­ers nev­er served, win­ning TMB-based OK for Keytru­da

6 years ago
Pharma

Am­i­cus shares surge as Sanofi strug­gles to raise a cheer for mixed piv­otal da­ta for a PhI­II con­tender — and ...

6 years ago
R&D

All in on IL-11, Fra­zier un­veils lat­est start­up with dual fo­cus on fi­bro­sis and can­cer

6 years ago
Financing
Startups

FDA warns Take­da over asep­tic pro­cess­ing, in­ad­e­quate in­ves­ti­ga­tions

6 years ago
FDA+

Covid-19 roundup: No­vavax re­cruits As­traZeneca vet as its new CMO — right af­ter David Mott jumps on the board; ...

6 years ago
Coronavirus

A Bay Area up­start with leg­endary god­fa­thers breaks cov­er, tout­ing claims of a cu­ra­tive tech, uni­corn sta­tus and a ...

6 years ago
Financing
Startups

UP­DAT­ED Dew­point nabs ex-Sanofi CEO Brandi­court and Bay­er VC chief Eck­hardt for board

6 years ago
People

Pro­tein degra­da­tion pi­o­neer C4 Ther­a­peu­tics nabs $170M; Barcelona start­up has €30M to go af­ter can­cer metas­tases

6 years ago
News Briefing

Adding bil­lions in val­ue, Eli Lil­ly suc­ceeds where Pfiz­er failed, halt­ing breast can­cer re­cur­rence

6 years ago
R&D

Pablo cap­i­tal­ized: Roy­al­ty Phar­ma scores $2.2B IPO — the biggest of the year

6 years ago
Financing

FDA ap­proves first ther­a­peu­tic video game

6 years ago
FDA+

Take­da spins out a pipeline of ‘in­ter­est­ing but still dif­fi­cult’ psych drugs in $2B deal as it wraps up a ...

6 years ago
Deals
R&D

A fail­ure at Eli Lil­ly, the come­back drug teplizum­ab shows off more up­beat di­a­betes da­ta in the run-up to an FDA ...

6 years ago
R&D
First page Previous page 831832833834835836837 Next page Last page
A service from the Financial Times